GlobeNewswire by notified

Clariant announces simplified organizational and leadership structure

Share

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

  • Clariant to reorganize in three global Business Units instead of five, with newly appointed BU Presidents Angela Cackovich, Jens Cuntze, and Christian Vang
  • Executive Committee to be replaced by an Executive Steering Committee that will include the BU Presidents with P&L responsibility
  • Simplified and flatter operating model to support cultural transformation and implementation of Clariant’s purpose-led growth strategy
  • Change of organizational structure to result in fewer hierarchical layers and less complexity
  • Launch of Diversity, Equity and Inclusion (DE&I) roadmap as an integral part of Clariant’s purpose-led strategy Greater chemistry – between people and planet”
  • Ambitious 2030 targets for gender equality, an inclusive culture and cultural identity

  MUTTENZ, JUNE 22, 2022

Clariant, a focused, sustainable, and innovative specialty chemical company, today announced changes to its leadership and organizational structure as part of the company’s ongoing initiatives to implement its purpose-led strategy and cultural transformation. The new operating model allows Clariant to position itself for long-term sustainable growth while remaining committed to its strategic priorities, focusing on customers, innovation, sustainability, and people. Clariant also revealed its Diversity, Equity and Inclusion (DE&I) roadmap with a focus on gender equality, an inclusive culture and cultural identity.

As part of the reorganization, Clariant will slim down the number of Business Units (“BU”) from five to three and locate the BU Presidents in the regions with the largest customer base and highest growth potential for the respective businesses. It will also create a new Executive Steering Committee that will include the CEO, the CFO and the Presidents of the new Business Units, who will have full P&L responsibility. The new structure will enable Clariant to reduce hierarchical layers and overall complexity across its business functions. It is expected to foster greater accountability, speed up decision-making processes and enhance customer proximity, while strengthening diversity.

“Clariant has undergone a successful portfolio change in recent years and is now a true specialty chemicals company. Now is the right time to align the organization more closely to customers, businesses and markets. The new setup will further strengthen our position as a leader in sustainability and establish a best-in-class governance,” said Günter von Au, Chairman of the Board of Clariant.

“With our new operating model and cultural transformation, we will foster better customer orientation, greater empowerment, accountability and transparency and take a new approach to leadership development promoting an inclusive and diverse culture – thereby securing Clariant’s position to achieve its 2025 targets, in line with our purpose-led strategy,” said Conrad Keijzer, Clariant’s Chief Executive Officer.

Clariant will combine its existing BU Catalysts and Business Line Biofuels & Derivatives into one single BU called “Catalysts”, Functional Minerals and Additives into “Adsorbents & Additives”, and Industrial and Consumer Specialties and Oil and Mining Services into “Care Chemicals”. The reorganization has no impact on the financial reporting by Business Area within the current fiscal year.

The new businesses will be headed by newly appointed BU Presidents Angela Cackovich, Jens Cuntze, and Christian Vang. By being located in their biggest growth regions, they will further increase their customer proximity.

Angela Cackovich will be the newly appointed President, of the BU Adsorbents & Additives and the EMEA region. She will join Clariant`s Executive Steering Committee from Tesa, where she was a member of the Executive Committee. She gained significant industry experience in several positions, including at Henkel, Celanese, Rohm & Haas as well as Dow Corning and Hoechst. As a German citizen she holds a master’s degree in chemical engineering.

With almost 20 years at Clariant, Jens Cuntze has extensive experience within the company. He will become President, of the BU Catalysts and the Asia-Pacific region. Previously, he was Head of Corporate Planning & Strategy after serving in various leadership roles including Head of Petrochemical Catalysts and Head of Procurement. He holds a Diploma and PhD in Chemistry from ETH Zurich and is German.

Christian Vang will become President, of the BU Care Chemicals and the Americas region. He has more than 14 years of leadership experience within Clariant. His latest positions included Head of BU Industrial and Consumer Specialties and Head of Corporate Planning & Strategy. Prior to joining Clariant in 2008, Christian worked in leading positions at Siegwerk, SICPA and Hempel. He holds degrees from Harvard, Insead and London Business School, and is a Danish national.

With the elimination of the Chief Transformation Officer (CTO) and Chief Operating Officer (COO) roles, the new structure enables direct reporting lines of Clariant’s BUs to the CEO. As a consequence of the new structure, Hans Bohnen, Chief Operating Officer, and Bernd Hoegemann, Chief Transformation Officer, have decided to step down from their current roles in the Executive Committee and will pursue their career outside the company. “We are very grateful to Bernd and Hans for their very valuable contributions in various leadership positions at Clariant. I wish them the very best for the future,” said Conrad Keijzer.

Clariant will ensure additional transparency and accountability by moving away from its current structure of an Executive Committee with a sole oversight and review role. Instead, the Company will have a new Executive Steering Committee that will include CEO Conrad Keijzer, CFO Bill Collins as well as the three BU Presidents effective July 1st, 2022.

Together with Chief Human Resources Officer Tatiana Berardinelli, General Counsel Alfred Muench, newly appointed Chief Corporate Development Officer Chris Hansen, and Chief Technology & Sustainability Officer Richard Haldimann, the Executive Steering Committee will form the Executive Leadership Team. By bringing all key functions together when it comes to important strategic decisions, Clariant will speed up decision making, strengthen its governance and increase accountability.

To complement the structural changes by a diversity-based culture, Clariant also launched its DE&I roadmap. It is an essential part of Clariant’s new purpose-led strategy, aimed at building a more diverse, equitable and inclusive future by focusing on gender equality, an inclusive culture and cultural identity. For each of these areas, Clariant has set ambitious targets for 2030 that are accompanied by a variety of concrete actions.

In terms of gender equality, Clariant strives to provide equal opportunities for all genders with a special focus on strengthening the gender balance at the management level by doubling the current female representation to at least 30% by 2030. When it comes to cultural identity, Clariant wants to provide equal access to career development for all ethnicities and ensure that the business footprint is reflected in the company’s leadership. To reflect Clariant’s global setup, the organization strives to increase the share of leaders with national origin outside of Europe from currently 32% to more than 40% by 2030.

The transformation of Clariant's structure and culture will help the Company to bring its core businesses to their full potential and fully leverage its purpose: Greater chemistry – between people and planet.

CORPORATE MEDIA RELATIONS



Jochen Dubiel
Phone +41 61 469 63 63
jochen.dubiel@clariant.com




Anne Maier
Phone +41 61 469 63 63
anne.maier@clariant.com



Ellese Caruana
Phone +41 61 469 63 63
ellese.caruana@clariant.com

INVESTOR RELATIONS



Andreas Schwarzwälder
Phone +41 61 469 63 73
andreas.schwarzwaelder@clariant.com



Maria Ivek
Phone +41 61 469 63 73
maria.ivek@clariant.com



Alexander Kamb
Phone +41 61 469 63 73
alexander.kamb@clariant.com

Follow us on Twitter, Facebook, LinkedIn, Instagram.

This media release contains certain statements that are neither reported financial results nor other historical information. This document also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant’s ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company’s ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.

www.clariant.com

Clariant is a focused, sustainable, and innovative specialty chemical company based in Muttenz, near Basel/Switzerland. On 31 December 2021, Clariant totaled a staff number of 11 537 and recorded sales of CHF 4.372 in the fiscal year for its continuing businesses. The company reports in three Business Areas: Care Chemicals, Catalysis, and Natural Resources. Clariant’s corporate strategy is led by the overarching purpose of ‘Greater chemistry – between people and planet’ and reflects the importance of connecting customer focus, innovation, sustainability, and people.



Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy30.6.2022 10:00:00 CEST | Press release

First-line tislelizumab plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal squamous cell carcinoma1 Statistically significant survival benefit with tislelizumab plus chemotherapy was observed regardless of PD-L1 status and consistent across all patient subgroups1 Novartis to discuss results of multi-regional RATIONALE 306 study, the seventh positive Phase III trial readout for tislelizumab, with regulatory health authorities Basel, June 30, 2022 — Today Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) as a first-line treatment for adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status. Tislelizumab plus chemotherapy demonstrated a median OS of 17.2 months (CI, 15.8-20.1 months) versus 10.6 m

Huhtamaki publishes 2022 Half-yearly Report on July 21, 202230.6.2022 09:00:00 CEST | Press release

HUHTAMÄKI OYJ PRESS RELEASE 30.6.2022 AT 10:00 Huhtamaki publishes 2022 Half-yearly Reporton July21, 2022 Huhtamäki Oyj will publish its 2022 Half-yearly Report on Thursday, July 21, 2022, approximately at 8.30 am Finnish time (EEST). The release and related results presentation material will be available after publishing at www.huhtamaki.com/investors. Teleconference Huhtamaki will arrange a combined audiocast and teleconference on the same day at 9.30 am Finnish time, where the company’s management will present the results. The event will be followed by a Q&A session. The event will be held in English, it can be followed real-time at: https://huhtamaki.videosync.fi/2022-q2 If you wish to ask questions, please dial one of the following numbers 5-10 minutes prior to the call start: Finland Toll: +358981710310 Sweden Toll: +46 856642651 United Kingdom Toll: +44 3333000804 United States Toll: +1 6319131422 Confirmation code for the call is 23337170# An on-demand replay of the audiocast w

Fingerprints announces design win for its optical under-display solution with major Asian smartphone OEM30.6.2022 08:00:00 CEST | Press release

Fingerprint Cards AB (Fingerprints™) today announced that it has secured a design win* for its optical under-display solution, FPC 1632, with a major Asian smartphone OEM, following successful qualification tests earlier this year. We expect to commence shipments during the fourth quarter of 2022. “Since many years, Fingerprints is a well-established world leader in capacitive fingerprint sensors. The design win we are announcing today marks our entry into a new market segment: optical under-display fingerprint sensors. This will open up attractive new growth opportunities for us going forward, and our goal is to capture a significant share of this market,” says Ted Hansson, President Mobile, PC & Access China at Fingerprints. For more information about Fingerprints’ mobile device solutions, visit the website. * Fingerprints’ definition of Design Win (DW): The decision by a device vendor (OEM or ODM) to start development of one or several commercial product(s) incorporating Fingerprint

Inaugural Yara Clean Ammonia Capital Markets Day30.6.2022 08:00:00 CEST | Press release

Oslo, 30 June 2022: Today, Yara International ASA (“Yara”) will host a Capital Markets Day (“CMD”) for Yara Clean Ammonia (“YCA” or the “Company”). During the event, members of YCA’s management team will present key features of the Company, including its strategy and growth ambitions, as well as financial parameters and targets for the future. In May 2022, Yara announced that it is evaluating a potential initial public offering (“IPO”) of YCA on the Oslo Stock Exchange. “While the decision to list YCA will be made in due course, Yara is now excited to host an inaugural CMD for YCA to showcase their exciting story,” said Svein Tore Holsether, CEO and President of Yara. “YCA combines a leading midstream business with exceptional growth prospects and a value creating project portfolio.” Key highlights: Clean ammonia represents a massive opportunity that is projected to drive exponential, long-term market growth [1].YCA comprises existing cash flows from a market leading position [2] in a